MOD GRF 129 - 5mg
MOD GRF (1-29), also known as CJC-1295 without DAC, is a synthetic peptide analog derived from the first 29 amino acids of naturally occurring growth hormone–releasing hormone (GHRH). It is modified with four amino acid substitutions to improve stability and half-life compared to the unmodified version (Sermorelin).
A synthetic analog of growth hormone–releasing hormone (GHRH), modeled for laboratory research.
MOD GRF (1-29), also known as CJC-1295 without DAC, is a synthetic peptide analog derived from the first 29 amino acids of naturally occurring growth hormone–releasing hormone (GHRH). It is modified with four amino acid substitutions to improve stability and half-life compared to the unmodified version (Sermorelin).
In research settings, MOD GRF (1-29) stimulates the anterior pituitary to release growth hormone in a pulsatile manner, mimicking natural secretion patterns. This growth hormone release influences numerous physiological processes in experimental models, including tissue growth, metabolism, recovery, and repair mechanisms.
Titan research and immune system function
Growth Hormone Secretion Models:
Investigated for its role in stimulating pulsatile growth hormone release in experimental settings.
Metabolic Regulation:
Studied for potential effects on fat metabolism, lean muscle retention, and energy utilization.
Recovery & Repair Research:
Research explores its role in tissue healing, muscle recovery, and cellular repair mechanisms.
Anti-Aging Pathways:
Interest in its ability to replicate youthful growth hormone secretion patterns in aging models.
Synergistic Peptide Combinations:
Often studied alongside GHRP-class peptides to amplify growth hormone release in lab settings.
Titan research and immune system function
Pulsatile GH Release:
Mimics natural growth hormone rhythms, avoiding constant elevated levels in experimental protocols.
Tissue Regeneration Studies:
Supports repair processes in muscle, tendon, and connective tissues.
Metabolic Enhancement:
May improve lipid utilization and energy efficiency in models of metabolic dysregulation.
(1) Modified GRF (1-29)—Wikipedia overview of analog structure and pharmacokineticshttps://en.wikipedia.org/wiki/Modified_GRF_%281%E2%80%9129%29
(2) Modified GRF (1-29) & GHRP-2: Studies in Hormones & Metabolismhttps://www.corepeptides.com/modified-grf-1-29-ghrp-2-studies-in-hormones-metabolism-and-growth/
(3) Mod GRF 1-29 & Ipamorelin Blend: Growth Hormone Secretion & Metabolic Regulationhttps://biotechpeptides.com/2025/01/15/modified-grf-1-29-ipamorelin-blend-studies-in-growth-hormone-secretion-and-metabolic-regulation/
The chart shows the effects of Gonadorelin on LH (luteinizing hormone) stimulation over four weeks in human clinical data. Starting at Week 1, LH secretion increased by about 150%, rising further to 200% by Week 2.
By Week 4, LH levels reached a 250% increase, highlighting a steady upward trend. This suggests that Gonadorelin produces a strong and progressive boost in hormone secretion with continued use.
Form:
Lyophilized Powder
Storage (unreconstituted):
- Store at 2–8 °C (refrigerated), protected from light.
- For long-term storage, keep at –20 °C.
- Avoid repeated freeze–thaw cycles.
Reconstitution:
- Reconstitute with sterile water for injection or 0.9% NaCl immediately prior to use. Use aseptic technique.
Storage (after reconstitution):
- Store at 2–8 °C.
- Use within 7–10 days.
- Discard any unused solution after this period.
- Handle under sterile conditions.
- Do not shake vigorously (may cause peptide denaturation).
- Inspect visually for particulate matter or discoloration before use.
Issued for quality verification of tested material.
Feedback highlighting proven outcomes and reliability.
